Intradigm’s lead product candidate ICS-283 is a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathway. The product uses an RGD peptide as the ligand to target av-expressing endothelial cells. ICS-283 is currently in the preclinical stage. Data from several in vivo models including xenograft models of different cancers (colorectal, renal, head and neck, and breast) have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as a validated target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm systemic delivery of RNAi in man.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/21/06 | Series A | 16M | Unknown | |
| 01/01/09 | Series B | 21.4M | Unknown |
People
Phillip Haworth (CEO)
Samuel Zalipsky (VP Technology Development)
Martin Woodle (Chief Scientific Officer)
Xiao-Dong Yang (VP Research & Preclinical Development)
Wei-Wu He (Board Member)
News
Intradigm closes $21.4M for cancer therapeutics
January 8, 2009 4:49 am
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4… Continue reading ⟩
Intradigm lands $18.5M to advance oncology treatment
October 3, 2008 8:04 pm
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a… Continue reading ⟩
Life-science briefing: Thursday, April 10, 2008
April 10, 2008 4:07 pm
TODAY’S HEADLINES: HealthExtras buys venture-backed PBM HospiScript for $100M (release) Urological device-maker NeoTract adds $7.4M (VentureWire) RNAi-drug startup Intradigm seeks… Continue reading ⟩